


XCOPRI® (cenobamate tablets) CV is indicated for the treatment of partial-onset seizures in adult patients.

DISCOVER THE POSSIBILITY OF ZERO SEIZURES WITH NEW XCOPRI¹

In a study of adult patients with partial-onset seizures taking **XCOPRI**:

2X GREATER SEIZURE REDUCTION WITH XCOPRI VS PLACEBO¹


The primary outcome: Median percentage **reduction in 28-day seizure frequency**



*Statistically significant compared with placebo.

AS MANY AS 1 IN 5 PATIENTS EXPERIENCED ZERO SEIZURES¹

A prospectively defined, secondary outcome: Patients achieving **seizure reductions of 100%**



STUDY DESIGNS:

The efficacy of XCOPRI as adjunctive therapy in partial-onset seizures was established in 2 multicenter, randomized, double-blind, placebo-controlled studies in adult patients (Study 1 and Study 2). Patients had partial-onset seizures with or without secondary generalization and were not adequately controlled with 1 to 3 concomitant antiepileptic drugs. Study 1 [N=221] compared XCOPRI 200 mg/day with placebo. Study 2 [N=434] compared XCOPRI 100 mg/day, 200 mg/day, and 400 mg/day with placebo. The double-blind treatment period consisted of a titration phase (6 weeks) and a maintenance phase (6 weeks for Study 1 and 12 weeks for Study 2). In both studies, patients were started on a higher starting dose and/or faster titration than the Prescribing Information recommendation. The primary endpoint was median percentage reduction in 28-day seizure frequency during the double-blind treatment period.¹

IMPORTANT SAFETY INFORMATION and INDICATION for XCOPRI® (cenobamate tablets) CV

CONTRAINDICATIONS

XCOPRI is contraindicated in any patients with known hypersensitivity to the compound or any of the components of the drug product.

XCOPRI is contraindicated in patients with Familial Short QT syndrome.

WARNINGS AND PRECAUTIONS

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Also known as Multiorgan hypersensitivity, has been reported in patients taking antiepileptic drugs, including XCOPRI. DRESS has been reported, including one fatality, when XCOPRI is titrated rapidly (weekly or faster titration). No cases of DRESS were reported in an open-label safety study of 1339 partial-onset seizure patients when XCOPRI was initiated at 12.5 mg/day and titrated every two weeks. This finding does not establish that the risk of DRESS is prevented by a slower titration; however, XCOPRI should be initiated at 12.5 mg once daily and titrated every two weeks. DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy, in association with other organ system involvement. Eosinophilia is often present. If such signs or symptoms are present, the patient should be evaluated immediately. XCOPRI should be discontinued immediately and not restarted if an alternative etiology for the signs or symptoms cannot be established.

QT Shortening: XCOPRI can cause shortening of the QT interval. Caution should be used when administering XCOPRI and other drugs that shorten the QT interval as there may be a synergistic effect on the QT interval that would increase the QT shortening risk.

Please see additional Important Safety Information on the reverse side and accompanying full Prescribing Information.







XCOPRI™
(cenobamate tablets) CV
12.5 • 25 • 50 • 100 • 150 • 200 mg

PRESCRIBING AND DOSING XCOPRI

XCOPRI[™]
(cenobamate tablets) CV
12.5 • 25 • 50 • 100 • 150 • 200 mg

Once-daily **XCOPRI** is titrated at 2-week intervals¹

XCOPRI® (cenobamate tablets) CV can be prescribed as **monotherapy or adjunctive therapy**.¹

WEEKS 1-2	WEEKS 3-4	WEEKS 5-6	WEEKS 7-8	WEEKS 9-10	WEEK 11 & THEREAFTER
12.5 mg once daily	25 mg once daily	50 mg once daily	100 mg once daily	150 mg once daily	200 mg once daily (recommended maintenance dosage)
					

Not actual sizes.

XCOPRI SAFETY

Most common **adverse reactions** (≥10% for **XCOPRI** and greater than placebo)^{1*}

	SOMNOLENCE	DIZZINESS	FATIGUE	DIPLOPIA	HEADACHE
XCOPRI 400 mg/day (n=111)	37%	33%	24%	15%	10%
XCOPRI 200 mg/day (n=223)	22%	22%	14%	7%	12%
XCOPRI 100 mg/day (n=108)	19%	18%	12%	6%	10%
PLACEBO (n=216)	11%	15%	7%	2%	9%

*Safety information is based on pooled data from Study 1 and Study 2.

Discover the possibilities of **zero seizures** at XCOPRI.com

IMPORTANT SAFETY INFORMATION and INDICATION for XCOPRI® (cenobamate tablets) CV (cont'd)

Suicidal Behavior and Ideation: Antiepileptic drugs (AEDs), including XCOPRI, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Advise patients, their caregivers, and/or families to be alert for these behavioral changes and report them immediately to a healthcare provider.

Neurological Adverse Reactions: XCOPRI causes dose-dependent increases in the neurologic adverse reactions including, dizziness, diplopia, disturbance in gait and coordination, somnolence, and fatigue.

Prescribers should advise patients against engaging in hazardous activities requiring mental alertness, such as operating motor vehicles or dangerous machinery, until the effect of XCOPRI is known.

Withdrawal of AEDs: As with all antiepileptic drugs, XCOPRI should generally be withdrawn gradually because of the risk of increased seizure frequency and status epilepticus. But if withdrawal is needed because of a serious adverse event, rapid discontinuation can be considered.

MOST COMMON ADVERSE REACTIONS

In adult adjunctive therapy placebo-controlled clinical studies, the most common adverse reactions that occurred in XCOPRI-treated patients (incidence at least 10% and greater than placebo) were somnolence, dizziness, fatigue, diplopia, headache.

XCOPRI should be initiated at **12.5 mg once daily** and **titrated every 2 weeks**

- The **recommended maintenance dosage** of XCOPRI is **200 mg once daily**

XCOPRI may be taken any time with or without food. Swallow tablets whole with liquid. Do not crush or chew.

Maximum dosage: If needed based on clinical response and tolerability, dosage may be increased above 200 mg/day by increments of 50 mg/day every 2 weeks to a maximum of 400 mg/day.

For patients with mild or moderate hepatic impairment, the maximum recommended dosage is 200 mg once daily.



From **benefits verification to patient assistance**, SK life science navigator is designed to help your patients prescribed **XCOPRI** get started and continue on therapy if appropriate.

To speak with a care coordinator, call **866.SK.NAVIG** or visit **XCOPRI.com/SKNAV.com**.

DOSING CONSIDERATIONS

Dosage adjustment of XCOPRI or other concomitant medications may be necessary.

- Consider gradually reducing phenytoin dosages by up to 50% during initial titration.
- Consider reducing dosages of phenobarbital and clobazam as needed when used concomitantly with XCOPRI. When XCOPRI and carbamazepine or lamotrigine are taken concomitantly, consider increasing dosages as needed of carbamazepine or lamotrigine.
- Consider increasing dosages as needed of drugs which are CYP2B6 and CYP3A substrates and decreasing dosages as needed of drugs which are CYP2C19 substrates.
- Effectiveness of hormonal oral contraceptives may be reduced when administered concomitantly with XCOPRI. Women should use additional or alternative non-hormonal birth control.

Dosage reduction of XCOPRI may be considered in patients with mild to moderate and severe renal impairment. XCOPRI use is not recommended in end-stage renal disease.

The maximum recommended daily dose is 200 mg for patients with mild or moderate hepatic impairment. XCOPRI use is not recommended in patients with severe hepatic impairment.

DRUG ABUSE

XCOPRI is a Schedule V controlled substance.

INDICATION

XCOPRI is indicated for the treatment of partial-onset seizures in adult patients.

Please see accompanying full Prescribing Information.

Reference: 1. XCOPRI [package insert]. Paramus, NJ: SK Life Science, Inc.

For any medical questions or to report an adverse event, please contact Medical Information at 1-866-657-5574.
© 2020 SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd. PM-US-XCOP-0023 04/20